Ventana and BD Biosciences to Co-Market DNA Microarrays and Analysis System | GenomeWeb

NEW YORK, July 11 – Ventana Medical Systems and BD Biosciences Clontech Laboratories have agreed to non-exclusively co-market their microarray products, the companies said Wednesday.

Together, the two companies will co-promote BD Biosciences’ DNA microarrays, and Ventana’s microarray analysis platform. Financial details of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.